Clinical Trials · NCT04915144

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Name: 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnPhase 2Octreotide

Phase: Phase 2
Recruitment status: Withdrawn
Sponsor: British Columbia Cancer Agency
Enrollment: 0
Start date: Jan 2023
Locations: 1 site, Canada
Primary endpoint: Determine whether personalized 177Lu-DOTATOC PRRT reduces adverse events (AE).

View Octreotide compound reference